-
1.发明申请Method of Preparation of Pitavastatin and Pharmaceutical Acceptable Salts Thereof 审中-公开匹伐他汀及其可接受的盐的制备方法公开(公告)号：US20150152061A1
公开(公告)日：2015-06-04
申请号：US14479575
申请日：2014-09-08
IPC分类号： C07D215/14
CPC分类号： C07D215/14
摘要： The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.
摘要翻译： 本发明公开了一种化合物，其是匹伐他汀的碱金属或碱土金属盐，其中碱金属或地球金属包含镁，锌，钾，锶和钡中的一种或多种。
-
公开(公告)号：US10435363B2
公开(公告)日：2019-10-08
申请号：US15366229
申请日：2016-12-01
发明人： Shriprakash Dhar Dwivedi , Ramesh Chandra Singh , Rajendra Gokalbhai Chavda , Jagdish Maganlal Patel , Daya Ram Pal , Pranav Jitendra Gangwar , Vikas Patel , Vishwadeepak Rama Pati Tripathi
IPC分类号： C07D207/33 , C07D207/333 , C07D207/325 , A61K31/402 , C07D207/32
摘要： The present invention provides pyrroles having hypolipidemic hypocholesteremic activities. The invention provides saroglitazar and its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof. The invention also provides a process for the preparation of saroglitazar. The invention further provides intermediates as well process for preparation thereof.
-
公开(公告)号：US09714225B2
公开(公告)日：2017-07-25
申请号：US15035876
申请日：2014-11-13
发明人： Shriprakash Dhar Dwivedi , Jayprakash Ajitsingh Parihar , Alpeshkumar Pravinchandra Shah , Samir Rameshbhai Gajjar , Brij Khera
IPC分类号： A61K31/55 , C07D223/16
CPC分类号： C07D223/16
摘要： The present invention relates to stable crystalline Form I of lorcaserin hydrochloride of Formula (IA) and processes for its preparation. The invention also relates to processes for the preparation of lorcaserin and pharmaceutically acceptable salts, solvates and hydrates thereof.
-
4.发明申请PROCESS FOR THE PREPARATION OF DABIGATRAN ETEXILATE MESYLATE AND POLYMORPHS OF INTERMEDIATES THEREOF 有权制备DABIGATRAN ETEXILATE MESYLATE的方法及其中间体的聚合公开(公告)号：US20150011589A1
公开(公告)日：2015-01-08
申请号：US14373163
申请日：2013-01-21
IPC分类号： C07D401/12 , C07D213/75
CPC分类号： C07D401/12 , C07D213/75 , Y10T428/2982
摘要： The present invention provides crystalline form of intermediates of Formula 2A, The present invention also provides process for the preparation of dabigatran etexilate mesylate; polymorph of intermediates thereof; particularly processes for the preparation of crystalline form of intermediates. The present invention also relates to the use of crystalline intermediates for the preparation of dabigatran etexilate mesylate.
摘要翻译： 本发明提供式2A中间体的结晶形式。本发明还提供制备甲磺酸达比加群酯的方法。 其中间体的多晶型物; 特别是制备中间体结晶形式的方法。 本发明还涉及结晶中间体用于制备甲磺酸达比加群酯的用途。
-
公开(公告)号：US09382209B2
公开(公告)日：2016-07-05
申请号：US14818236
申请日：2015-08-04
发明人： Shriprakash Dhar Dwivedi , Ashok Prasad , Mukul Hariprasad Sharma , Piyush Rajendra Sharma , Jayprakash Ajitsingh Parihar
CPC分类号： C07D223/16 , B65B7/02 , B65B31/00 , B65B61/20 , B65D31/02 , B65D31/04 , B65D81/266 , C07B2200/13 , C30B7/02 , C30B29/54 , Y10T428/2982
摘要： Stable crystalline Form II and stable crystalline Form III of ivabradine hydrochloride and processes for their preparation are disclosed.
-
6.发明授权Method of preparation of pitavastatin and pharmaceutical acceptable salts thereof 有权匹伐他汀及其药学上可接受的盐的制备方法公开(公告)号：US09139527B2
公开(公告)日：2015-09-22
申请号：US14479575
申请日：2014-09-08
IPC分类号： C07D215/14
CPC分类号： C07D215/14
摘要： The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.
摘要翻译： 本发明公开了一种化合物，其是匹伐他汀的碱金属或碱土金属盐，其中碱金属或地球金属包含镁，锌，钾，锶和钡中的一种或多种。
-
公开(公告)号：US09120755B2
公开(公告)日：2015-09-01
申请号：US14358025
申请日：2012-11-12
发明人： Shriprakash Dhar Dwivedi , Ashok Prasad , Mukul Hariprasad Sharma , Piyush Rajendra Sharma , Jaiprakash Ajitsingh Parihar
IPC分类号： C07D223/16
CPC分类号： C07D223/16 , B65B7/02 , B65B31/00 , B65B61/20 , B65D31/02 , B65D31/04 , B65D81/266 , C07B2200/13 , C30B7/02 , C30B29/54 , Y10T428/2982
摘要： Stable crystalline Form II and stable crystalline Form III of ivabradine hydrochloride and processes for their preparation are disclosed.
摘要翻译： 公开了稳定的晶型II和盐酸伊伐布雷定的稳定晶型III及其制备方法。
-
公开(公告)号：US08962851B2
公开(公告)日：2015-02-24
申请号：US13727338
申请日：2012-12-26
IPC分类号： C07D401/00 , A61K31/44 , C07D401/12
CPC分类号： C07D401/12
摘要： The present invention discloses one pot process for enantioselective synthesis of single enantiomers of substituted sulphoxides 2-(2-pyridinylmethylsulphinyl)-1H-benzimidazoles or said compounds in an enantiomerically enriched form.
摘要翻译： 本发明公开了一种用于对映选择性合成取代的亚砜2-（2-吡啶基甲基亚磺酰基）-1H-苯并咪唑或所述化合物的对映异构体富集形式的单一对映异构体的一种方法。
-
公开(公告)号：US20150051228A1
公开(公告)日：2015-02-19
申请号：US14384567
申请日：2013-03-12
发明人： Shriprakash Dhar Dwivedi , Ashok Prasad , Kuldeep Natwarlal Jain , Kumar Kamlesh Singh , Jitendra Maganbhai Gajera
IPC分类号： C07D473/04
CPC分类号： C07D473/04 , C07D473/06 , Y10T428/2982
摘要： The present invention relates to an amorphous form of linagliptin and processes for the preparation thereof. The invention also relates to a pharmaceutical composition comprising therapeutically effective amount of an amorphous form of linagliptin and use of said composition for treatment of diabetes especially type-I or type-II, prediabetes or reduction of glucose tolerance.
摘要翻译： 本发明涉及无定形形式的利格列汀及其制备方法。 本发明还涉及药物组合物，其包含治疗有效量的无定形形式的利格列汀，并且所述组合物用于治疗糖尿病尤其是I型或II型，糖尿病前期或葡萄糖耐量降低的用途。
-
10.发明申请AMORPHOUS FORM OF APIXABAN, PROCESS OF PREPARATION AND COMPOSITIONS THEREOF 审中-公开APIXABAN的非晶形式，其制备方法及其组合物公开(公告)号：US20150018386A1
公开(公告)日：2015-01-15
申请号：US14383521
申请日：2013-03-05
发明人： Shriprakash Dhar Dwivedi , Kamlesh Kumar Singh , Jitendra Maganbhai Gajera , Nitin Tandon , Digambar Ware
IPC分类号： A61K31/4545
CPC分类号： A61K31/4545 , A61K9/146 , C07D471/04 , Y10T428/2982
摘要： The present invention discloses an amorphous form of apixaban, process of preparation and compositions thereof.
摘要翻译： 本发明公开了阿哌沙班的无定形形式，其制备方法及其组合物。
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.019 秒)
